These include inhibitors of histone deacetylase 6 (panobinostat), an inhibitor of Exportin-1 (selinexor, considered efficient in combination with dexamethazone), the DNA intercalating drugs anthracyclines (doxorubicin), and the BCL2 inhibitor venetoclax, which does not yet have approval for treatment of MM but appears to be efficient against MM with t(11;14) rearrangement [87,126,127]. The gene discussed is XPO1; the disease is Miyoshi myopathy.